Back to list

IL-37

University of North Carolina at Chapel Hill


Description

to test whether the highly significant genetic variants of IL-37 underlie the hyper-inflammatory trait seen among periodontitis patients.


Keywords:

Mouth/Nose/Throat, Tooth/Dental


Category:

Medical Treatment Outcomes

Qualifications

 


Age
18 - 65 years


Gender
Any


Study Population

Generally healthy, caucasian adults that are rare variant IL-37 genotype. (Specific protein arrangement being studied only found in Caucasians).


Investigator

Silvana Barros
Associate Professor
Periodontology

For questions, contact:

S.T. Phillips
sherrill_phillips@unc.edu
(919) 537-3422
Visit Website

Recruitment Period End

December 31, 2019

Location

Primary Location
UNC School of Dentistry
385 S Columbia St, Chapel Hill, NC 27599, USA
Secondary Location
General & Oral Health Center

Study Qualifications

Gender Any

Age Range 18 - 65 years

Participant qualification(s) Subjects must have read, understood and signed an informed consent form in English. Subjects must be able and willing to follow study procedures and instructions in English. Subjects must be adult Caucasian males or females between the ages of 18 and 65 years (inclusive). Subjects must present with at least 20 teeth in the functional dentition, excluding third molars. Subjects must have at least 3 teeth in each posterior sextant.

Not eligible if: Chronic disease with oral manifestations including diabetes mellitus. Current smoker or one that has stopped smoking less than 2 years prior to enrollment. Gross oral pathology Treatment with antibiotics for any medical or dental condition within 1 month prior to the screening examination. Chronic treatment (i.e., two weeks or more) with any medication known to affect periodontal status (e.g., phenytoin, calcium antagonists, cyclosporin, coumadin, non-steroidal anti-inflammatory drugs, aspirin) within one month of the screening examination. Ongoing medications initiated less than three months prior to enrollment (i.e., medications for chronic medical conditions must be initiated at least three months prior to enrollment). Significant organ disease including impaired renal function, heart murmur, history of rheumatic fever or valvular disease, or any bleeding disorder. Infectious diseases such as hepatitis, HIV or tuberculosis. Anemia or other blood dyscrasias. Anticoagulant therapy or drugs, such as heparin or warfarin. Severe unrestored caries, or any condition that is likely to require antibiotic treatment over the trial. Pregnant, or expect to become pregnant within the next several months. Females of child-bearing capacity must be willing to have pregnancy test to confirm they are not pregnant. Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.

Number of Visits

    » 3 In person visit(s)

    screening, baseline, 6-week follow-up

    » 0 Remote visit(s)

Participation Period

6 to 8 weeks

Compensation

$40

By clicking I am interested, your contact information will be sent to the researcher/study coordinator for this study. The coordinator will respond by email with additional information on how to proceed.